Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 8/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208366 | 0.83 | FYN (0.44) | FYN | |
| SCHEMBL5313274 | 0.82 | MAPT (0.44) | — | |
| SCHEMBL6107645 | 0.78 | ALDH1A1 (0.49) | — | |
| SCHEMBL6106796 | 0.78 | KDM4E (0.52) | — | |
| SCHEMBL6106706 | 0.78 | RAB9A (0.49) | — | |
| SCHEMBL6105830 | 0.74 | FYN (0.45) | FYN | |
| SCHEMBL5210473 | 0.71 | PTGS1 (0.46) | — | |
| SCHEMBL5943291 | 0.70 | MAPT (0.44) | FYN | |
| SCHEMBL14557173 | 0.70 | LMNA (0.43) | FYNKDRCDC7PIK3CDPIK3CB | |
| SCHEMBL24378416 | 0.70 | PDE10A (0.50) | FYNKDRFLT3GSK3BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453830-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS ANTIHERPES AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | GUDMUNDSSON KRISTJAN | 2007-07-12 | — | — | US | disclosed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040248903-A1 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | HRH4, HRH2, HRH1 | MAPK14 1854/4885FYN 2956/4885KDR 2463/4885 |
| US-20040248903-A1 | Pyrazolo-pyridine derivatives as antiherpes agents | HRH4, HRH1, HRH2 | MAPK14 1959/4885FYN 2905/4885KDR 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.